DEVELOPMENTAL FUNDS. During the current grant period, MSKCC opened the first phase of the Zuckerman Research Center. This allowed additional space for MSKCC to expand its laboratory-based cancer research efforts. An effort to attract leading laboratory-based junior investigators was begun in 2006. The strategic planning for these recruitments was undertaken by the Senior Leadership and executed by search committees led by the Program Leaders with participation from the membership. To date, 17 junior investigators have been recruited and established independent laboratories in part supported by the CCSG funds. Over the last 6 years, a total of $4.7M in developmental funds were awarded to assist in establishing their laboratories. These funds have been instrumental in the success of these junior investigators at establishing successful independent laboratories. As a group they have received $38.1M in peer-reviewed funding (total award) and produced over 80 publications from their laboratories. All 8 of the laboratory-based research programs participated in and benefited from this influx of emerging talent. Many of the new investigators brought with them expertise in new areas or techniques of relevance to the evolving scope of cancer research. Funds are now being requested to support the mission of the Cancer Center in two categories critical to the advancement of its goals: 1) Additional faculty recruitment in disciplines related to the strategic vision of the Center and 2) Pilot project grants to stimulate cross-disciplinary collaboration between investigators in the Survivorship, Outcomes and Risk (SOAR) program and members of other Cancer Center programs. Both categories represent opportunities for the Center to strengthen and diversify its research portfolio. Funds requested to support faculty recruitment in strategic areas will enable the Center to attract top talent by providing a start-up/transition package that will enable new recruits to have the resources to immediately develop and grow their research programs. Funds requested to support cross-disciplinary pilot projects between SOAR and other Cancer Center program members will provide an opportunity for the development and initiation of research projects that build upon the expertise of the Center's population scientists, as well as exploit the knowledge of the Center's basic and clinical research community in order to facilitate the discovery of new knowledge.

Public Health Relevance

The recruitment of faculty in strategic areas, as well as the initiation of pilot projects bridging population sciences with other areas of investigation are critical elements to facilitating the discovery of new cancer-related knowledge.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-50
Application #
8986751
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2016-01-01
Budget End
2016-12-31
Support Year
50
Fiscal Year
2016
Total Cost
$1,421,601
Indirect Cost
$621,601
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Basaraba, Cale N; Westhoff, Carolyn L; Pike, Malcolm C et al. (2017) Estimating systemic exposure to levonorgestrel from an oral contraceptive. Contraception 95:398-404
Hernandez, Jonathan M; Beylergil, Volkan; Goldman, Debra A et al. (2017) Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. Ann Surg :
Argani, Pedram; Kao, Yu-Chien; Zhang, Lei et al. (2017) Primary Renal Sarcomas With BCOR-CCNB3 Gene Fusion: A Report of 2 Cases Showing Histologic Overlap With Clear Cell Sarcoma of Kidney, Suggesting Further Link Between BCOR-related Sarcomas of the Kidney and Soft Tissues. Am J Surg Pathol 41:1702-1712
Moore, Kathleen N; Martin, Lainie P; O'Malley, David M et al. (2017) Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol 35:1112-1118
Lee, Ser Yee; Goh, Brian K P; Sadot, Eran et al. (2017) Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor. Ann Surg Oncol 24:202-210
Hyman, David M; Taylor, Barry S; Baselga, José (2017) Implementing Genome-Driven Oncology. Cell 168:584-599
Li, Gang G; Somwar, Romel; Joseph, James et al. (2017) Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations. Clin Cancer Res 23:2981-2990
Bhagat, Tushar D; Zou, Yiyu; Huang, Shizheng et al. (2017) Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer. J Biol Chem 292:837-846
Prieto-Granada, Carlos N; Zhang, Lei; Antonescu, Cristina R et al. (2017) Primary cutaneous adenoid cystic carcinoma with MYB aberrations: report of three cases and comprehensive review of the literature. J Cutan Pathol 44:201-209
He, Mu; Agbu, Stephanie; Anderson, Kathryn V (2017) Microtubule Motors Drive Hedgehog Signaling in Primary Cilia. Trends Cell Biol 27:110-125

Showing the most recent 10 out of 7561 publications